Two independent studies concluded that the loss of RBM3 expression was an unfavorable marker in CRC [29], and that high expression of RBM3 was an independent marker for prolonged overall survival in CRC patients [30]. This evidence concerns the gene RBM3 and colorectal carcinoma.